Investor Presentation Full Year 2021

17 Investor presentation Full year 2021 Financial outlook for 2022 Sales growth - at CER Expectations 2 February 2022 6% to 10% Sales growth - reported Operating profit growth - at CER Operating profit growth - reported Around 5 percentage points higher 4% to 8% Around 7 percentage points higher Financial items (net) Effective tax rate Free cash flow Loss of around DKK 2.8 billion 20% to 22% DKK 50 to 55 billion Note: Changes since last highlighted in bold The financial outlook is based on an assumption of a continuation of the current business environment and given the current scope of business activities and has been prepared assuming that currency exchange rates remain at the level as of 28 Jan 2022 Novo NordiskⓇ

View entire presentation